Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

142 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer.
Nitz U, Gluz O, Clemens M, Malter W, Reimer T, Nuding B, Aktas B, Stefek A, Pollmanns A, Lorenz-Salehi F, Uleer C, Krabisch P, Kuemmel S, Liedtke C, Shak S, Wuerstlein R, Christgen M, Kates RE, Kreipe HH, Harbeck N; West German Study Group PlanB Investigators. Nitz U, et al. Among authors: wuerstlein r. J Clin Oncol. 2019 Apr 1;37(10):799-808. doi: 10.1200/JCO.18.00028. Epub 2019 Feb 20. J Clin Oncol. 2019. PMID: 30785826 Clinical Trial.
Health-related quality of life in male breast cancer patients.
Kowalski C, Steffen P, Ernstmann N, Wuerstlein R, Harbeck N, Pfaff H. Kowalski C, et al. Among authors: wuerstlein r. Breast Cancer Res Treat. 2012 Jun;133(2):753-7. doi: 10.1007/s10549-012-1970-3. Breast Cancer Res Treat. 2012. PMID: 22315132
[Breast cancer. Individualized therapy concepts].
Harbeck N, Wuerstlein R. Harbeck N, et al. Among authors: wuerstlein r. Internist (Berl). 2013 Feb;54(2):194-9. doi: 10.1007/s00108-012-3156-9. Internist (Berl). 2013. PMID: 23371261 German.
Health economic impact of risk group selection according to ASCO-recommended biomarkers uPA/PAI-1 in node-negative primary breast cancer.
Jacobs VR, Kates RE, Kantelhardt E, Vetter M, Wuerstlein R, Fischer T, Schmitt M, Jaenicke F, Untch M, Thomssen C, Harbeck N. Jacobs VR, et al. Among authors: wuerstlein r. Breast Cancer Res Treat. 2013 Apr;138(3):839-50. doi: 10.1007/s10549-013-2496-z. Epub 2013 Apr 9. Breast Cancer Res Treat. 2013. PMID: 23568480 Clinical Trial.
142 results